Welcome to our dedicated page for Qiagen news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen stock.
Qiagen N.V. (QGEN) delivers essential molecular testing solutions powering advancements in healthcare, research, and applied sciences. This dedicated news hub provides investors and professionals with authoritative updates on Qiagen's innovations in sample preparation, automated diagnostics, and bioinformatics.
Access real-time announcements including earnings reports, regulatory milestones, and strategic partnerships. Our curated collection features press releases on product launches, clinical study collaborations, and technology integrations across molecular diagnostics and life sciences.
Key updates cover Qiagen's expanding portfolio for precision medicine, infectious disease testing, and next-generation sequencing workflows. Track developments in critical areas like companion diagnostics and laboratory automation solutions serving global healthcare providers and research institutions.
Bookmark this page for streamlined access to Qiagen's official communications. Stay informed about the company's progress in transforming biological insights into actionable results across 40+ countries.
QIAGEN (NYSE: QGEN) has announced the successful placement of new senior, unsecured net share settled convertible bonds due 2032. The offering totals $750 million in aggregate principal amount with a 2.0% annual coupon payable semi-annually.
The convertible bonds will feature an initial conversion price set at a 40% premium over the reference share price, which will be determined based on the volume weighted average price of QIAGEN shares on the NYSE on August 28, 2025. The company has agreed to a 90-day lock-up period following the settlement date, during which it won't sell similar securities or shares, subject to certain exceptions.
QIAGEN (NYSE: QGEN) has announced plans to issue senior, unsecured net share settled convertible bonds due 2032. The offering, targeted at non-US institutional investors, will have an aggregate volume of USD 750 million with minimum denominations of USD 200,000 each.
The bonds will have a 7-year maturity and feature an interest rate of 1.75% to 2.25% per annum, payable semi-annually. The conversion will involve approximately 11.2 million shares, representing about 5.1% of QIAGEN's current outstanding share capital. The initial conversion price will be set at a 40% to 45% premium over the reference share price.
The settlement date is scheduled for September 4, 2025, and the bonds will be traded on the Open Market segment of the Frankfurt Stock Exchange. The proceeds will be used for general corporate purposes, including refinancing existing debt.
QIAGEN (NYSE: QGEN) reported strong Q2 2025 results, exceeding guidance with net sales of $534 million, representing a 7% increase at actual rates and 6% at constant exchange rates (CER). The company achieved an adjusted operating income margin of 29.9%, up 1.5 percentage points from Q2 2024, and delivered adjusted diluted EPS of $0.60.
Key growth drivers included QIAstat-Dx (+41% CER) and QuantiFERON (+11% CER), contributing to an 11% CER growth in diagnostic solutions. Based on strong H1 2025 performance, QIAGEN increased its FY 2025 outlook to 4-5% CER net sales growth and reaffirmed its adjusted diluted EPS target of $2.35 CER. The company has returned over $350 million to shareholders in 2025 through a synthetic share repurchase and its first-ever cash dividend.
QIAGEN (NYSE: QGEN) has launched QIAseq xHYB Long Read Panels, a new suite of target enrichment solutions designed for long-read sequencing of complex genomic regions. The panels are optimized for native long-read platforms, including PacBio's technology, and aim to improve analysis of structural variants, HLA typing, and repeat expansions.
Built on QIAGEN's hybrid-capture chemistry, the panels offer high target completeness, flexible formats including fixed panels for hereditary cancers and HLA typing, compatibility with high-molecular-weight DNA extraction kits, and integration with QIAGEN Digital Insights bioinformatics. The launch strengthens QIAGEN's position in providing solutions for both short- and long-read NGS technologies.
QIAGEN (NYSE: QGEN) has scheduled its Q2 2025 earnings release and conference call. The company will release its second quarter results on Tuesday, August 5, 2025, after market close at 22:05 Frankfurt time (21:05 London/16:05 New York).
The earnings conference call will be held the following day, Wednesday, August 6, at 15:30 Frankfurt time (14:30 London/09:30 New York). Participants can join through multiple channels including call-back registration, direct dial-in, or audio webcast. A replay of the conference call will be made available afterward.
QIAGEN (NYSE: QGEN) announced significant leadership changes and shareholder-friendly initiatives. Stephen H. Rusckowski, former Chairman, President and CEO of Quest Diagnostics, has been elected as Chairman of the Supervisory Board, succeeding Lawrence A. Rosen who stepped down after 12 years of service.
At the Annual General Meeting (AGM), with 80.4% shareholder representation, all proposed resolutions were approved, including two major financial initiatives: the company's first-ever annual cash dividend of $0.25 per share (approximately $54 million total) and a new synthetic share repurchase authorization of up to $500 million.
Following the AGM, QIAGEN's Supervisory Board now consists of eight members, implementing a planned reduction to historical levels while maintaining necessary expertise for the company's future development.
FAQ
What is the current stock price of Qiagen (QGEN)?
What is the market cap of Qiagen (QGEN)?
